Do Australian immunoglobulin products meet international measles antibody titer standards?
Authors:
- 20 October 2016
- journal article
- research article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 13 (3) , 607-612
Abstract
The effectiveness of passive immunisation post-exposure to measles appears subject to a dose-response effect. New Zealand and the United Kingdom have increased the recommended dose of polyclonal human immunoglobulin for post-exposure prophylaxis within the last decade in response to concerns about decreasing levels of measles antibodies in these products. This study used the plaque-reduction neutralization test (PRNT) to measure the titer of measles-specific antibodies in Australian immunoglobulin products for post-exposure prophylaxis and compared the utility of an enzyme-linked immunosorbent assay (ELISA) to the PRNT in available Australian and international samples: Australian intramuscular (n = 10), Australian intravenous (n = 28), New Zealand intramuscular (n = 2), Hizentra (subcutaneous)(USA) (n = 3), and Privigen (intravenous)(USA) (n = 2). Measles titres in Australian IM and IV immunoglobulins ranged from 51 to 76 IU/mL and 6 to 24 IU/mL respectively, as measured by PRNT calibrated to the WHO 3rd international standard. ELISA titres were variable but higher than PRNT titres in all tested samples. Measles antibody titres in Australian immunoglobulin products meet consensus-prescribed international thresholds. Development of a convenient, standardized, readily accessible assay for determination of measles titres in immunoglobulin products would be useful for future studies and facilitate international comparisons.Keywords
This publication has 14 references indexed in Scilit:
- Post-exposure passive immunisation for preventing measlesCochrane Database of Systematic Reviews, 2014
- Imported measles outbreaks prompt call for parents to vaccinate their childrenCanadian Medical Association Journal, 2014
- The significance for epidemiological studies anti-measles antibody detection examined by enzyme immunoassay (EIA) and plaque reduction neutralization test (PRNT).2014
- Passive immunization for the public health control of communicable diseases: Current status in four high-income countries and where to nextHuman Vaccines & Immunotherapeutics, 2013
- Prevention of Measles, Rubella, Congenital Rubella Syndrome, and Mumps, 2013 Summary Recommendations of the Advisory Committee on Immunization Practices (ACIP)2013
- Progress in global measles control, 2000–2010.2012
- Development and evaluation of an automatable focus reduction neutralisation test for the detection of measles virus antibodies using imaging analysisJournal of Virological Methods, 2011
- Humoral and Cellular Immune Responses to Measles and Tetanus: The Importance of Elapsed Time Since Last Exposure and the Nature of the AntigenJournal of Clinical Immunology, 2010
- Current efficacy of postexposure prophylaxis against measles with immunoglobulinThe Journal of Pediatrics, 2001
- Epidemiology of Transmissible Diseases after EliminationAmerican Journal of Epidemiology, 2000